Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages 18-79 years, inclusive~* Fasting, untreated non-high-density lipoprotein cholesterol (non-HDL-C) level above NCEP ATPIII goals~* Fasting, untreated triglyceride (TG) level in the high to very high range~* Provide written informed consent and authorization for protected health information disclosure~Exclusion Criteria:~* Pregnancy~* Use of lipid-altering drugs which cannot be stopped~* History of certain cardiovascular conditions or cardiac surgery within prior 6 months~* Body mass index above 40 kg per square meter~* Allergy or sensitivity to omega-3 fatty acids or to statin drugs~* Poorly-controlled conditions including diabetes, hypertension, or thyroid disease~* Certain muscle, liver, kidney, lung, or gastrointestinal conditions~* Certain medications~* Active cancers treated within prior 2 years (except non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- atorvastatin arm (Type: ACTIVE_COMPARATOR): atorvastatin + placebo
- Lovaza arm (Type: EXPERIMENTAL): Lovaza + atorvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).